76

Pharmanutra SpAFRA Pharmanutra Stock Report

Last reporting period 30 Sep, 2023

Updated 29 Oct, 2024

Last price

Market cap $B

0.624

Micro

Exchange

XFRA - Deutsche Boerse AG

761.F Stock Analysis

76

Uncovered

Pharmanutra SpA is uncovered by Eyestock quantitative analysis.

Market cap $B

0.624

Dividend yield

3.17 %

Shares outstanding

9.646 B

Pharmanutra SpA develops nutraceutical products and medical devices. The company is headquartered in Pisa, Pisa. The company went IPO on 2017-07-18. The firm develops nutraceutical products and medical devices. The company focuses on studying and producing formulations that are backed up in scientific research. The company is able to cover all stages of the development of a product, from its design, formulation and registration to its marketing, distribution and training of its commercial representatives. The firm offers Gestalys DHA, a nutritional supplement; Cetilar, a massage coadiuvant, improves and brings relief to joints affected by osteoarthritis; Cetilar patch, a transdermic patch containing a concentrated formulation of cetylated fatty acids (CFA) esters; SiderAL Forte; CardioSiderAL; SiderAL Folico; SiderAL; Bonecal and Novomega, among others.

View Section: Eyestock Rating